Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This trial is a Phase 2, randomized, controlled study to compare the degree of mucosal injury
after the oral administration of an investigational product, PL2200, and a marketed 325 mg
immediate-release aspirin product. Each group will be treated with either an
immediate-release aspirin tablet or PL2200 capsule at 325 mg per day for 6 weeks, and
evaluated via an endoscope for any gastrointestinal injury that may have been caused by study
medication.